Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
University of Colorado, Denver
BicycleTx Limited
Case Comprehensive Cancer Center
Maastricht University Medical Center
Bolt Biotherapeutics, Inc.
Memgen, Inc.
Incyte Corporation
Providence Health & Services
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
DEKA Biosciences
University of California, San Diego
The Clatterbridge Cancer Centre NHS Foundation Trust
University of Pittsburgh
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Compugen Ltd
Ikena Oncology
UNICANCER
University of Cincinnati
University Hospital, Ghent
Dana-Farber Cancer Institute
The Netherlands Cancer Institute
Bristol-Myers Squibb
Fate Therapeutics
Bristol-Myers Squibb
Fate Therapeutics
Jules Bordet Institute
Celgene
Presage Biosciences
Presage Biosciences
Five Prime Therapeutics, Inc.
Oncovir, Inc.
MultiVir, Inc.
Incyte Corporation
Bristol-Myers Squibb